Amylyx Pharmaceuticals (AMLX) Net Cash Flow (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Net Cash Flow of $2.6 million for Q1 2026, up 114.57% year-over-year from $1.2 million in Q1 2025, and up 91.38% quarter-over-quarter from $1.4 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Net Cash Flow (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Net Cash Flow history runs 6 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 114.57% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $168.1 million (up 252.96% YoY), while the FY2025 annual figure was $147.7 million, up 261.19% from the prior year.
- Net Cash Flow for Q1 2026 stood at $2.6 million, up from $1.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $166.5 million in Q3 2025, with the low at -$112.4 million in Q3 2023.
- The 5-year median for Net Cash Flow is $1.4 million (2025), against an average of $10.5 million.
- Peak annual rise in Net Cash Flow reached 6325.65% in 2025, while the deepest fall reached 3965.73% in 2025.
- Amylyx Pharmaceuticals' Net Cash Flow stood at -$45.7 million in 2022, then jumped by 175.92% to $34.7 million in 2023, then tumbled by 82.48% to $6.1 million in 2024, then slumped by 77.69% to $1.4 million in 2025, then surged by 91.38% to $2.6 million in 2026.
- Business Quant data shows AMLX's Net Cash Flow at $2.6 million in Q1 2026, $1.4 million in Q4 2025, and $166.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.35 Bn | 4.35 Bn | - | -179.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -179.74 Mn |
| Jun 30, 2026 | -179.74 Mn |
| Mar 31, 2026 | 2.60 Mn |
| Mar 31, 2026 | 2.60 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Sep 30, 2025 | 166.47 Mn |
| Sep 30, 2025 | 166.47 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Mar 31, 2025 | -17.82 Mn |
| Mar 31, 2025 | -17.82 Mn |
| Dec 31, 2024 | 6.08 Mn |
| Dec 31, 2024 | 6.08 Mn |
| Sep 30, 2024 | -2.67 Mn |
| Sep 30, 2024 | -2.67 Mn |
| Jun 30, 2024 | -95.51 Mn |
| Jun 30, 2024 | -95.51 Mn |
| Mar 31, 2024 | 461,000.00 |
| Mar 31, 2024 | 461,000.00 |